- Conditions
- Agitation, Alzheimer's Disease
- Interventions
- AVP-923-20, Placebo, AVP-923-30
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 51
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Episodic Migraine
- Interventions
- Dextromethorphan and quinidine, Placebo
- Drug
- Lead sponsor
- Cady, Roger, M.D.
- Individual
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
- Conditions
- Multiple Sclerosis
- Interventions
- AVP-923
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 17 more
- Conditions
- Atrial Fibrillation, Arrhythmia
- Interventions
- Rate Control, Ablation Therapy, Rhythm control
- Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 10
- States / cities
- Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more
- Conditions
- Arrhythmia
- Interventions
- quinidine, no therapy
- Drug
- Lead sponsor
- International Registry of Asymptomatic Brugada Syndrome
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Nuedexta, Matching Placebo
- Drug
- Lead sponsor
- Center for Neurologic Study, La Jolla, California,
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Grand Rapids, Michigan + 4 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- Placebo, AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 93
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more
- Conditions
- Paroxysmal Atrial Fibrillation
- Interventions
- Radiofrequency ablation, antiarrhythmic drugs, Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs, ThermoCool Radiofrequency Catheter
- Device · Drug
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 45
- States / cities
- Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Healthy
- Interventions
- Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Cypress, California • South Miami, Florida • San Antonio, Texas
- Conditions
- Hepatitis B
- Interventions
- EDP-514, Itraconazole, Carbamazepin, Quinidine
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- dextromethorphan HBr and quinidine sulfate
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Fort Lauderdale, Florida • Gainesville, Florida
- Conditions
- COVID-19
- Interventions
- EDP-235, Itraconazole, Carbamazepine, Quinidine
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Agitation in Participants With Dementia of the Alzheimer's Type
- Interventions
- AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 79
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 61
- States / cities
- Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
- Conditions
- Pseudobulbar Affect (Involuntary Laughing and/or Crying)
- Interventions
- NUEDEXTA®
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Miami, Florida • Centerville, Ohio
- Conditions
- Advanced Chronic Liver Disease, Healthy Participants
- Interventions
- AZD2389, Quinidine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Disinhibition Syndrome
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Major Depressive Disorder, Treatment Resistant
- Interventions
- dextromethorphan/quinidine
- Drug
- Lead sponsor
- James Murrough
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Orforglipron, Midazolam, Quinidine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- RSV Infection
- Interventions
- EDP-938, Itraconazole, Rifampin, Quinidine
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Intermittent Explosive Disorder
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more
- Conditions
- Atrial Fibrillation, Heart Failure
- Interventions
- FDA approved rate and rhythm control drugs, AV Node ablation and device implant
- Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more